Susquehanna International Group, LLP Ampio Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.08 - $21.0 $8,424 - $2.21 Million	-105,312 Reduced 47.57%	116,076 $7,000
Q2 2022 Aug 15, 2022	BUY	$0.16 - $0.47 $32,944 - $96,775	205,905 Added 1329.88%	221,388 $37,000
Q1 2022 May 16, 2022	SELL	$0.42 - $0.62 $25,305 - $37,355	-60,250 Reduced 79.56%	15,483 $7,000
Q4 2021 Feb 14, 2022	SELL	$0.56 - $1.71 $92,090 - $281,206	-164,448 Reduced 68.47%	75,733 $43,000
Q3 2021 Nov 15, 2021	SELL	$1.21 - $1.8 $410,551 - $610,738	-339,299 Reduced 58.55%	240,181 $399,000
Q2 2021 Aug 11, 2021	SELL	$1.56 - $1.98 $692,081 - $878,411	-443,642 Reduced 43.36%	579,480 $968,000
Q1 2021 May 17, 2021	BUY	$1.36 - $2.49 $597,881 - $1.09 Million	439,619 Added 75.34%	1,023,122 $1.73 Million
Q4 2020 Feb 16, 2021	BUY	$0.75 - $2.76 $100,570 - $370,099	134,094 Added 29.84%	583,503 $928,000
Q3 2020 Nov 16, 2020	BUY	$0.61 - $1.17 $110,663 - $212,255	181,415 Added 67.69%	449,409 $430,000
Q2 2020 Aug 14, 2020	BUY	$0.47 - $0.72 $34,495 - $52,844	73,395 Added 37.72%	267,994 $171,000
Q1 2020 May 15, 2020	SELL	$0.36 - $0.74 $361,428 - $742,936	-1,003,968 Reduced 83.76%	194,599 $81,000
Q4 2019 Feb 14, 2020	BUY	$0.35 - $0.58 $280,731 - $465,212	802,090 Added 202.3%	1,198,567 $699,000
Q3 2019 Nov 14, 2019	BUY	$0.38 - $0.52 $69,271 - $94,792	182,294 Added 85.11%	396,477 $199,000
Q1 2018 May 15, 2018	BUY	$2.16 - $3.48 $359,588 - $579,336	166,476 Added 348.96%	214,183 $728,000
Q4 2017 Feb 14, 2018	BUY	$0.68 - $4.19 $32,440 - $199,892	47,707	47,707 $194,000

96.6K

Ticker AMPE
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,287,008
Market Cap $2.26M
Description
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.